Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 15/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 6/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226518 | 1.00 | HDAC4 (1.00) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2225769 | 0.94 | HDAC4 (0.89) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL29757316 | 0.94 | HDAC4 (0.88) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2226555 | 0.93 | HDAC4 (0.87) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14605297 | 0.91 | HDAC4 (0.82) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14752448 | 0.88 | HDAC4 (0.79) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2228678 | 0.86 | HDAC4 (0.76) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2362796 | 0.83 | HDAC4 (0.71) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL25049598 | 0.83 | HDAC8 (0.71) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14752493 | 0.83 | HDAC4 (0.71) | HDAC4HDAC1HDAC8HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250177529-A1 | ACOUSTIC ENRICHMENT OF ADOPTIVE CELL TRANSFERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| US-20250115871-A1 | METHODS TO IMPROVE ENDURING HEMATOPOIETIC STEM CELL TRANSPLANTATION | TRAILHEAD BIOSYSTEMS INC. | 2025-04-10 | — | — | US | claimed |
| US-20250090473-A1 | Macrophage Targeted Immunotherapeutics | THE GENERAL HOSPITAL CORPORATION | 2025-03-20 | — | — | US | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2024259376-A2 | NON-VIRAL CELL ENGINEERING | ARSENAL BIOSCIENCES, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| US-20240366784-A1 | INJECTABLE HYDROGEL COMPOSITIONS AND METHODS OF USE THEREOF | DREXEL UNIVERSITY | 2024-11-07 | — | — | US | claimed |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-31 | — | — | US | claimed |
| WO-2023167842-A2 | ACOUSTIC ENRICHMENT OF ADOPTIVE CELL TRANSFERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-09-07 | — | — | WO | claimed |
| WO-2023147573-A2 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2023-08-03 | — | — | WO | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2023101943-A1 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023081884-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2023074794-A1 | METHOD OR AGENT WITH HDAC REGULATOR, FOR TREATMENT OF DIABETES AND COMPLICATIONS | 国立大学法人滋賀医科大学 | 2023-05-04 | — | — | WO | claimed |
| CN-115778950-A | Application of histone deacetylase inhibitor TMP195 in preparation of medicines for promoting osteogenesis | 山西医科大学第二医院 | 2023-03-14 | — | — | CN | claimed |
| US-20230039816-A1 | METHOD FOR INDUCING HEPATOCYTE PLASTICITY | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2023-02-09 | — | — | US | claimed |
| WO-2022192300-A1 | STEM CELL DIFFERENTIATION AND POLYMERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-09-15 | — | — | WO | claimed |
| CN-115040660-A | Mannitol modified nanoparticle and preparation method and application thereof | 南通大学 | 2022-09-13 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090473-A1 | Macrophage Targeted Immunotherapeutics | CD47, CAPG, CD74 | HDAC4 705/4885HDAC1 543/4885HDAC8 834/4885 |
| US-20240366784-A1 | INJECTABLE HYDROGEL COMPOSITIONS AND METHODS OF USE THEREOF | CD44, PLOD3, TP53 | HDAC4 3391/4885HDAC1 3551/4885HDAC8 2257/4885 |
| US-20240358767-A1 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | EBP, AKT3, PRKCD | HDAC4 1053/4885HDAC1 512/4885HDAC8 1340/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC4 27/4885HDAC1 71/4885HDAC8 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.